Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL).
暂无分享，去创建一个
J. Leonard | I. Flinn | S. Coutre | Yeonhee Kim | N. Wagner-Johnston | W. Godfrey | N. Fowler | J. Sharman | J. Barrientos | R. Boccia | M. Schreeder | S. Vos | T. Boyd | L. Holes | D. Johnson | R. Dansey | Leanne Holes